Study Group: Tykerb Prescribers (US)
Council Members in this Study Group: 22
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Taral PatelOncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INC
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer,...
- Jon Strasser
Assistant Professor of Radiation Oncology
THOMAS JEFFERSON UNIVERSITYJon Strasser, MD, is an Assistant Professor of Radiation Oncology at Thomas Jefferson University and an Attending Physician in Radiology, Oncology, and Radiation Oncology at the Helen F. Graham Cancer Center of the Christiana Care Health System in Delaware....
Haitham Al-OkkAssistant Clinical Professor - Hematology-Oncology
Mahr Cancer CenterHaitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology....
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Particle Beam Technology - Costly and a limited utility
October 26, 2009
Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov
Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly by treating prostate cancer.Protons are incredibly useful in specific diseases - ie ocular melanoma, pediatric cancers, but are too costly without proven benefit for our health care system.
-
May 27, 2008
Look to England's example for ways to solve America's health-care problem | www.sltrib.com
A single payer, national system does work, but may not necessarily be in the best interest of all parties. Yes this type of system is 'free' to the users, but is funded through higher taxes than paid in the US.
-
February 19, 2008
Analysis by: Taral Patel, Oncologist,In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com
New data with low and high dose of Avastin with Taxoter
-
improve Overall survival in prostate cancer
February 19, 2008
Analysis by: Taral Patel, Oncologist,Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022). Data is very impressive. This may lead FDA approval in prostate cancer in next 3-6 months.
-
December 7, 2007
Analysis by: Taral Patel, Oncologist,F.D.A. Criticizes Avastin Use for Breast Cancer | www.nytimes.com
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never used Avastin to treat breast cancer, but he knows other doctors do, despite the lack of FDA’s blessing. “Physicians always want to do something for the patient,” he said. But he believes the panel’s vote “will make them think twice” before they try Avastin for breast cancer. “This drug is a good drug,” Buzdar added. “It does work in a number of other cancers where it not only prolongs control of the disease but it keeps more patients alive. In breast cancer, it has not panned out.”
Members in this Study Group include these company types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
- Consultancy, Healthcare-Focused
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Partner
- President
- Physician - Director
- Owner
- Physician - Division Head
- Medical Director
- Consultant
- Dean / Emeritus / Senior Fellow